Acacia Pharma announced that Scott Byrd and Christine Soden have joined its Board of Directors. Scott Byrd has 23 years of experience in the pharmaceutical industry. Most recently, he was the Chief Commercial Officer of Cadence Pharmaceuticals Inc. from June 2009 until the company's acquisition by Mallinckrodt Pharmaceuticals in March 2014 for $1.4 billion.

Scott was responsible for all Cadence's commercial activities, in particular, building and the company's US sales and marketing infrastructure for Ofirmev®, the post-operative pain control product. Previously, Scott served in a variety of US and global roles in sales, marketing, finance, manufacturing and strategic planning at Eli Lilly and Company since January 1992. Christine Soden is a chartered accountant and is the Chief Financial Officer of the Electrical Geodesics Inc. Previously she was the Chief Financial Officer of the Optos plc, BTG plc and Celltech-Chiroscience plc following senior finance roles with life sciences companies including Oxagen Limited and Medeva plc.

Christine has substantial experience with technology and commercialisation stage companies and is a non-executive director of Fertility Focus Limited and Tower Cold Chain Solutions Ltd.